- This event has passed.
mRNA Lecture Series 2: Lecture Two – mRNA Clinical Trials: Enhancing Research-Clinician Collaboration to Accelerate Patient Outcomes
February 20 @ 8:00 am - 11:00 am AEDT
Event Navigation
mRNA LECTURE SERIES 2:
Based on the demand and success of the first lecture series, mRNA Victoria and BioMelbourne Network, are pleased to host a second series of four lectures beginning in November 2023 for the Victorian RNA community.
These lectures present an opportunity for global leading specialists in the RNA field to share their knowledge with the local RNA community. The accompanying networking sessions are an opportunity to foster connections between researchers, industry and government to build a connected and collaborative ecosystem in Victoria.
Explore Series 1 lectures and recordings here
Series 2 comprises four lectures:
Lecture One: The RNA Platform: The Breadth of Possibility Beyond mRNA | Friday 10 November 2023, 8:00am – 11:00am
Lecture Two: mRNA Clinical Trials: Enhancing Research-Clinician Collaboration to Accelerate Patient Outcomes | Tuesday 20 February 2024, 8:00am – 11:00am
Lecture Three: Details tbc | Thursday 11 April 2024, 8:00am – 11:00am
Lecture Four: Details tbc | Tuesday 28 May 2024, 8:00am – 11:00am
SERIES 2 | LECTURE TWO | mRNA Clinical Trials: Enhancing Research-Clinician Collaboration to Accelerate Patient Outcomes
The agility of the mRNA platform provides new opportunities for innovation in the delivery of clinical trials that could accelerate and improve the drug development process. This lecture will explore the opportunities of mRNA clinical trials for researchers, clinicians and the broader sector and speakers will share their experiences from conducting their own mRNA clinical trials.
Who should attend?
The intended audience is those that have an interest in developing an mRNA candidate to take to clinical trials, researchers who have non-mRNA candidates who are exploring an accelerated option using the mRNA platform, and industry professionals, students and academics who are interested to learn more about the workforce opportunities to support the mRNA industry in the future.
Our speakers will explore the following topics:
Personalised cancer vaccine trials: challenges and opportunities – Professor Riccardo Dolcetti, Head, Clinical and Translational Immunotherapy, Peter MacCallum Cancer CentremRNA an opportunity to accelerate medicine development and increase your chance of success – Dr Iris Depaz, Country Medical Lead & Head of Medical Vaccines, Sanofi ANZThe emerging workforce for producing doses for clinical trials – broader opportunities for the Australian ecosystem – Associate Professor Jennifer Short, Director, Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce TrainingFacilitated by – Dr Kylie Quinn, Vice-Chancellor’s Research Fellow, School of Health and Biomedical Sciences, RMIT University
Lecture Two Details:
Date: Tuesday 20 February 2024
Time (AEDT):
7:45am: Guest arrival, registration
8:00am: Networking breakfast
9:00am: Welcome and opening remarks
9:15am: Presentations and Q&A
10:30am: Networking, tea and coffee
11:00am: Close
Format: In-person only
Venue: Treasury Theatre, Lower Plaza, 1 Macarthur Street, East Melbourne
REGISTRATION (IN PERSON ONLY)
BioMelbourne Network Members: $0
BioMelbourne Network Non Members: $85
CANCELLATION POLICY
Full refund given up to 7 days prior to the event.
No refunds within 7 days of the event.
About mRNA Victoria
mRNA Victoria is responsible for leading the Victorian Government’s commitment to establish a world-class mRNA and RNA industry in Victoria, by supporting supply chain, research and development for pre and clinical research, commercialisation and manufacturing investments.Its role is to identify key capabilities, gaps, opportunities and lead the Victorian Government’s engagement, investment and partnerships with domestic and international companies, researchers and stakeholders to build RNA capability.
This lecture series is delivered in partnership with mRNA Victoria and the State Government of Victoria
Professor Riccardo Dolcetti, Head, Clinical and Translational Immunotherapy, Peter MacCallum Cancer Centre
Prof. Riccardo Dolcetti is a clinician scientist with MD specialisations in Oncology and Clinical Immunology with >20y experience in translational research. He is currently the Head of Clinical and Translational Immunotherapy at the Peter MacCallum Cancer Centre, Victorian Comprehensive cancer centre and Department of Microbiology and Immunology Oncology, University of Melbourne.
The research of his lab is focused on the identification, validation and clinical exploitation of novel antigen-specific and cell-based immunotherapies and the development and clinical application of immune assays to monitor immune responses in cancer patients. He has a documented expertise in the field of colorectal, breast and brain cancers, melanoma and infection-driven tumours.
He recently co-developed a nanoparticle-based vaccination platform able to selectively deliver various types of antigens to the most potent antigen presenting cells in vivo and generate strong and specific immunity resulting in therapeutic efficacy. He successfully administered multi-institutional research programs and projects and published >270 peer-reviewed papers with >11,000 citations.
He had the privilege to be elected President of the Italian Society for Cancer Research (2012-13). He will contribute to the project with his expertise in the exploitation and optimisation of humanised mouse models to investigate vaccine immunogenicity and therapeutic efficacy.
The research of his lab is focused on the identification, validation and clinical exploitation of novel antigen-specific and cell-based immunotherapies and the development and clinical application of immune assays to monitor immune responses in cancer patients. He has a documented expertise in the field of colorectal, breast and brain cancers, melanoma and infection-driven tumours.
He recently co-developed a nanoparticle-based vaccination platform able to selectively deliver various types of antigens to the most potent antigen presenting cells in vivo and generate strong and specific immunity resulting in therapeutic efficacy. He successfully administered multi-institutional research programs and projects and published >270 peer-reviewed papers with >11,000 citations.
He had the privilege to be elected President of the Italian Society for Cancer Research (2012-13). He will contribute to the project with his expertise in the exploitation and optimisation of humanised mouse models to investigate vaccine immunogenicity and therapeutic efficacy.
Dr Iris Depaz, Country Medical Lead & Head of Medical Vaccines, Sanofi ANZ
Dr Iris Depaz has over twenty years of experience in the pharmaceutical industry and scientific research. Iris obtained her PhD in Biomedical Sciences at the University of Queensland, Australia where she also conducted postdoctoral research and was an Associate Lecturer. She joined industry in 2007 and has worked in a variety of medical and R&D roles at local, regional and global levels in two global pharmaceutical companies including Global Medical Lead for the MMR and Varicella vaccine franchise for GSK based in Belgium and Head of Global Medical Effectiveness at Sanofi Vaccines based in France. Iris completed her EMBA with Honors at the IMD Business School in Lausanne Switzerland in 2020.
Currently, Iris is the Country Medical Lead and Vaccines Head of Medical for Sanofi ANZ. In 2023, she was appointed as the Managing Director of the Sanofi Global Translational Science Hub based in Brisbane. Her focus is on fostering scientific collaborations, elevating scientific communication, and establishing strategic partnerships to optimize vaccines development, access and uptake. She has also led several digital health projects utilizing Natural Language Processing (AI), data analytics, blockchain technology and omnichannel solutions. Iris is also passionate about patient empowerment, improving health outcomes and equitable access.
Currently, Iris is the Country Medical Lead and Vaccines Head of Medical for Sanofi ANZ. In 2023, she was appointed as the Managing Director of the Sanofi Global Translational Science Hub based in Brisbane. Her focus is on fostering scientific collaborations, elevating scientific communication, and establishing strategic partnerships to optimize vaccines development, access and uptake. She has also led several digital health projects utilizing Natural Language Processing (AI), data analytics, blockchain technology and omnichannel solutions. Iris is also passionate about patient empowerment, improving health outcomes and equitable access.
Associate Professor Jennifer Short, Director, Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training
Associate Professor Jennifer Short is the Director of the Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training, Australia’s first dedicated mRNA workforce training centre. The Centre will draw on Monash’s exceptional pool of biotechnology talent and expertise and work closely with industry to deliver best-practice education and training programs across the mRNA vaccines and therapeutics pipeline – from research and development, through clinical trials and approval, to production scale-up and manufacture, and beyond.
Jennifer has been an academic at Monash University since 2002, and is a behavioural neuropharmacologist and educational researcher who has published in the fields of addiction, Alzheimer's disease/blood-brain barrier, active learning and student skills development. As an education leader, Jennifer guided the development of an integrated skills-based pharmaceutical science curriculum focussed on employability outcomes, producing graduates with knowledge and skills in all facets of pharmaceutical discovery and development.
Jennifer has been an academic at Monash University since 2002, and is a behavioural neuropharmacologist and educational researcher who has published in the fields of addiction, Alzheimer's disease/blood-brain barrier, active learning and student skills development. As an education leader, Jennifer guided the development of an integrated skills-based pharmaceutical science curriculum focussed on employability outcomes, producing graduates with knowledge and skills in all facets of pharmaceutical discovery and development.
Rebecca Skinner, Director of Research and Industry Development, mRNA Victoria
https://www.linkedin.com/in/rebeccaskinner/
Related Events
